Table 3 Point prevalence, sero-prevalence and sample frequencies
From: Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)
Visit | Visit 0 | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|---|---|---|---|---|---|---|---|
Month | Apr 2020 | May 2020 | May 2020 | Jun 2020 | Jun 2020 | Mar 2021 | Apr-Jun 2021 |
RT-qPCR tests performed, n | 1,865 | 1,747 | 1,687 | 1,632 | 1,546 | 0 | 1,329 |
RT-qPCR positive, n (%) (Point prevalence) | 12 (0.6%) | 2 (0.1%) | 1 (0.1%) | 2 (0.1%) | 0 (0.0%) | 7 (0.5%) | |
RT-qPCR positive, weighted, n (%) (Weighted point prevalence) | 3,773 (0.7%) | 674 (0.1%) | 320 (0.1%) | 549 (0.1%) | 0 (0%) | 2,734 (0.5%) | |
IgG-S serology tests performed, n | 1,865 | 1,743 | 1,683 | 1,629 | 1,543 | 0 | 1,324 |
IgG-S positive/borderline, n (%) | 39 (2.1%) | 39 (2.2%) | 43 (2.6%) | 37 (2.3%) | 39 (2.5%) | 644 (48.6%) | |
IgG-S positive/borderline, weighted, n (%) | 11,199 (2.2%) | 12,253 (2.4%) | 13,586 (2.7%) | 12,247 (2.4%) | 13,664 (2.7%) | 232,689 (45.3%) | |
Population corresponding to weighted sample a, N | 506,569 | 506,569 | 506,569 | 506,569 | 506,569 | 513,736 | |
Official cumulative number of cases, n (%) b | 3,139 (0.6%) | 3,197 (0.6%) | 3,228 (0.6%) | 3,301 (0.7%) | 3,577 (0.7%) | 70,406 (13.7%) | |
Cumulative IgG-S sero-prevalence, including vaccinated (as a proportion of the whole cohort), n (%) | 11,199 (2.2%) | 12,243 (2.4%) | 13,213 (2.6%) | 13,416 (2.6%) | 13,636 (2.7%) | 176,381 (34.3%) |